

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**10 x 2 ml dose Folding Carton**

**10 x 2 ml dose Booklet Label**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Equip T suspension for injection

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each 2 ml dose contains:

Concentrated immunopurified tetanus toxoid ( $\geq 30$  IU/ml) adsorbed onto aluminium phosphate.

**3. PACKAGE SIZE**

10 x 2 ml

**4. TARGET SPECIES**

Horses.

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Intramuscular use.

**7. WITHDRAWAL PERIODS**

Zero days.

**8. EXPIRY DATE**

Exp. {mm/yyyy}

**9. SPECIAL STORAGE PRECAUTIONS**

Store in a refrigerator.

Protect from light.

Do not freeze.

Keep the container in the outer carton.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Zoetis UK Limited

**14. MARKETING AUTHORISATION NUMBERS**

Vm 42058/4064

**15. BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING**  
**UNITS**  
**2 ml Vial Label 2 ml Syringe Label**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Equip T

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

Each 2 ml dose contains:

C.tetani toxiod

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

## **PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:**

### **PACKAGE LEAFLET**

#### **1. Name of the veterinary medicinal product**

Equip T suspension for injection

#### **2. Composition**

Each 2 ml dose contains:

##### **Active substance:**

Immunopurified Tetanus Toxoid                       $\geq 30$  IU/ml\*

\* IU: International units

Clear liquid suspension above a whitish/grey sediment which resuspends readily on shaking.

#### **3. Target species**

Horses.

#### **4. Indications for use**

For the active immunisation of horses of 5 months of age or older against tetanus to prevent mortality.

Onset of immunity: within 2 weeks of completion of the primary course

Duration of immunity: 3 years.

#### **5. Contraindications**

None.

#### **6. Special warnings**

Vaccinate healthy animals only.

##### Special precautions for safe use in the target species:

The efficacy of active immunisation of young foals against equine influenza will be influenced by the level of maternally derived antibodies. This will vary between individuals due to a number of factors, e.g. the immune status of the dam; adequacy of colostral intake by the foal, etc. The vaccine should not be used in foals below 5 months of age, and foals should not be vaccinated until maternally derived antibodies have fallen below protective levels.

In any animal population, there may be a small number of individuals which fail to respond fully to vaccination. Successful vaccination depends upon correct storage and administration of the vaccine and the ability of the animal to respond. This can

be influenced by such factors as genetic constitution, intercurrent infection, age, nutritional status, concurrent drug therapy and stress.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

The product should be administered by respecting appropriate (aseptic) injection technique.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:

The vaccine may be used in pregnant mares which have been vaccinated against tetanus before pregnancy.

Heavily pregnant mares should not be subject to undue stress when vaccinated.

Interaction with other medicinal products and other forms of interaction:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Overdose:

Accidental overdosage is unlikely to cause any reactions other than those described in section 7.

Major incompatibilities:

Do not mix with any other veterinary medicinal product.

## **7. Adverse events**

Horses.

Rare (1 to 10 animals / 10,000 animals treated):
Injection site swelling <sup>1,3</sup> Stiffness <sup>1</sup> Elevated temperature <sup>1,2</sup>
Very rare (<1 animal / 10,000 animals treated, including isolated reports):
Injection site pain Hypersensitivity reaction <sup>4</sup>

<sup>1</sup> This condition normally resolves by the day following vaccination.

<sup>2</sup> Mild, transient, typically 9-12 hours post vaccination.

<sup>3</sup> Local, small (10-20 mm in diameter), soft, non-painful.

<sup>4</sup> In the event of an allergic or anaphylactic reaction, immediate treatment should be given with a soluble glucocorticoid intravenously or adrenalin intramuscularly.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. If you notice any side effects, even those not already

listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: [adverse.events@vmd.gov.uk](mailto:adverse.events@vmd.gov.uk)

## **8. Dosage for each species, routes and method of administration**

**Dose:** 2 ml.

**Administration:** Equip T should be shaken thoroughly before use and administered by deep intramuscular injection.

## **9. Advice on correct administration**

### **Primary vaccination**

Two injections of 2 ml with an interval of 4-6 weeks between them

### **Booster vaccination**

One dose 36 months after the primary course, repeated at intervals of up to 36 months.

## **10. Withdrawal periods**

Zero days.

## **11. Special storage precautions**

Keep out of the sight and reach of children.

Store in a refrigerator (2 °C - 8 °C).

Protect from light.

Do not freeze.

Keep the container in the outer carton.

Do not use this veterinary medicinal product after the expiry date which is stated on the label. The expiry refers to the last day of that month.

## **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon how to dispose of medicines no longer required.

### **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

### **14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES**

42058/4064

Type I glass vial with chlorobutyl rubber stopper and aluminium overseal.

Packaging: Box of 10 single-dose vials. Each box contains 10 sterile disposable 2 ml syringes and 10 sterile needles.

Type I glass syringe closed with bromobutyl rubber plunger stopper and tip cap.

Packaging: Box of 10 single-dose prefilled syringes with needles

Not all pack sizes may be marketed.

### **15. PID link (Do not print heading)**

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

### **16. Contact details**

Marketing authorisation holder and contact details to report suspected adverse reactions:

Zoetis UK Limited  
1st Floor, Birchwood Building  
Springfield Drive  
Leatherhead  
Surrey  
KT22 7LP  
Phone: +44 (0) 345 300 8034

Manufacturer responsible for batch release:

Zoetis Belgium  
Rue Laid Burniat 1  
1348 Louvain-La-Neuve  
Belgium

### **17. Other information**

Equip T stimulates active immunity against tetanus.

POM-V

Approved 04 August 2025

*Gavin Hall*